Paper · 34611482
Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma.
Doan HQ and 5 others. Oncotarget, 2021. Cited by 32 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma. Papers, record 34611482. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34611482
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References77
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31,319,387 | PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell Change. | J Natl Compr Canc Netw | 2019 | https://conductscience.org/library/papers/31319387 | PubMed |
| 2 | 29,400,712 | Noncanonical hedgehog pathway activation through SRF-MKL1 promotes drug resistance in basal cell carcinomas. | Nat Med | 2018 | https://conductscience.org/library/papers/29400712 | PubMed |
| 3 | 29,102,653 | Combination vismodegib and photodynamic therapy for multiple basal cell carcinomas. | Photodiagnosis Photodyn Ther | 2018 | https://conductscience.org/library/papers/29102653 | PubMed |
| 4 | 28,404,762 | Implementation of Systemic Hedgehog Inhibitors in Daily Practice as Neoadjuvant Therapy. | J Natl Compr Canc Netw | 2017 | https://conductscience.org/library/papers/28404762 | PubMed |
| 5 | 31,243,642 | Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma. | Target Oncol | 2019 | https://conductscience.org/library/papers/31243642 | PubMed |
| 6 | 25,759,019 | Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. | Cancer Cell | 2015 | https://conductscience.org/library/papers/25759019 | PubMed |
| 7 | 30,021,814 | Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. | Br J Ophthalmol | 2019 | https://conductscience.org/library/papers/30021814 | PubMed |
| 8 | 26,016,959 | Failure of vismodegib in advanced Basal cell carcinoma. | J Biol Regul Homeost Agents | 2015 | https://conductscience.org/library/papers/26016959 | PubMed |
| 9 | 25,759,020 | Smoothened variants explain the majority of drug resistance in basal cell carcinoma. | Cancer Cell | 2015 | https://conductscience.org/library/papers/25759020 | PubMed |
| 10 | 28,788,102 | Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease. | Int J Mol Sci | 2017 | https://conductscience.org/library/papers/28788102 | PubMed |
1 to 10 of 77
See all 77 referencesCited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 32 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,482,858 | Use of Hedgehog Pathway Inhibitors in Combination Therapy for Basal Cell Carcinoma: A Review and Narrative Synthesis. | J Clin Aesthet Dermatol | 2026 | https://conductscience.org/library/papers/42482858 | PubMed |
| 42,286,159 | Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study. | NPJ Precis Oncol | 2026 | https://conductscience.org/library/papers/42286159 | PubMed |
| 41,940,897 | Unraveling the molecular landscape: an overview on gene expression, epigenetic alterations, and therapeutic challenges in head and neck squamous cell carcinoma. | Mol Genet Genomics | 2026 | https://conductscience.org/library/papers/41940897 | PubMed |
| 41,888,999 | Pleural-Based GLI1-Altered Mesenchymal Tumor With ACTB-GLI1 Fusion: A Rare Pulmonary Entity Mimicking Synovial Sarcoma. | Thorac Cancer | 2026 | https://conductscience.org/library/papers/41888999 | PubMed |
| 41,543,881 | Alcian blue-positive stromal phenotype in basal cell carcinoma is associated with progression on first-line hedgehog inhibitors. | J Pathol Clin Res | 2026 | https://conductscience.org/library/papers/41543881 | PubMed |
| 40,507,247 | Electrochemotherapy in the Management of Keratinocyte Carcinomas: A Systematic Review. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40507247 | PubMed |
| 40,492,880 | Eight-Year Experience of Hedgehog Pathway Inhibitors at Three Tertiary Referral Centres in the Australian State of Victoria. | Australas J Dermatol | 2025 | https://conductscience.org/library/papers/40492880 | PubMed |
| 39,091,908 | Case report: Sequential treatment strategy for advanced basal cell carcinoma in Gorlin-Goltz syndrome: integration of vismodegib, radiotherapy, surgery, and high-intensity focused ultrasound. | Front Oncol | 2024 | https://conductscience.org/library/papers/39091908 | PubMed |
| 38,896,403 | Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies. | Am J Clin Dermatol | 2024 | https://conductscience.org/library/papers/38896403 | PubMed |
| 38,424,304 | Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets. | Nat Rev Cancer | 2024 | https://conductscience.org/library/papers/38424304 | PubMed |
1 to 10 of 21
See all 21 cited byGenes14
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| BRD4 | 23,476 | PubTator's text mining | https://conductscience.org/library/genes/23476 | NCBI Gene |
| CD274 | 29,126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| DYRK1B | 9,149 | PubTator's text mining | https://conductscience.org/library/genes/9149 | NCBI Gene |
| GLI1 | 2,735 | PubTator's text mining | https://conductscience.org/library/genes/2735 | NCBI Gene |
| GLI2 | 2,736 | PubTator's text mining | https://conductscience.org/library/genes/2736 | NCBI Gene |
| HDAC9 | 9,734 | PubTator's text mining | https://conductscience.org/library/genes/9734 | NCBI Gene |
| MRTFA | 57,591 | PubTator's text mining | https://conductscience.org/library/genes/57591 | NCBI Gene |
| PDCD1 | 5,133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| PIK3CD | 5,293 | PubTator's text mining | https://conductscience.org/library/genes/5293 | NCBI Gene |
| PTCH1 | 5,727 | PubTator's text mining | https://conductscience.org/library/genes/5727 | NCBI Gene |
1 to 10 of 14
See all 14 genesDrugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34611482
GET https://conductscience.org/api/papers/v1/34611482/references?page=2